Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Tough-to-Treat myeloma: early safety trial of HPN217 begins

NCT ID NCT04184050

Ongoing Disease control Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new drug called HPN217 in about 100 people whose multiple myeloma has returned or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also measure how the drug moves through the body over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA MULTIPLE MYELOMA IN RELAPSE MULTIPLE MYELOMA OF BONE MULTIPLE MYELOMA WITH FAILED REMISSION

Contacts and locations

Locations

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona, 85234, United States

  • Centre Hospitalier Universitaire De Nantes

    Nantes, 44093, France

  • Centre Hospitalier Universitaire de Poitiers

    Poitiers, 86021, France

  • Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD)

    Madrid, 28040, Spain

  • Josep Carreras Leukaemia Research Institute

    Barcelona, 08916, Spain

  • Mayo Clinic Arizona

    Phoenix, Arizona, 85054, United States

  • OHSU

    Portland, Oregon, 97239, United States

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14263, United States

  • The University of Kansas Cancer Center

    Fairway, Kansas, 66205, United States

  • UC San Diego Moores Cancer Center

    La Jolla, California, 92093, United States

  • University of Rochester James P Wilmot Cancer Institute

    Rochester, New York, 14642, United States

  • University of Washington - Seattle Cancer Center Alliance

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.